반응식
[NH:1]1[CH2:4][CH2:3][CH2:2]1.[CH3:5][N:6]1[C:10]([C:11](=[O:28])[NH:12][C:13]2[CH:14]=[CH:15][C:16]3[N:17]([N:19]=[C:20]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[N:21]=3)[CH:18]=2)=[C:9]([C:29](O)=[O:30])[CH:8]=[N:7]1>>[N:22]1([C:20]2[N:21]=[C:16]3[CH:15]=[CH:14][C:13]([NH:12][C:11]([C:10]4[N:6]([CH3:5])[N:7]=[CH:8][C:9]=4[C:29]([CH:4]4[NH:1][CH2:2][CH2:3]4)=[O:30])=[O:28])=[CH:18][N:17]3[N:19]=2)[CH2:23][CH2:24][O:25][CH2:26][CH2:27]1참가 물질
3
실험 절차
Using azetidine and 1-methyl-5-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-6-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid, the title compound was prepared in the same manner as described for example 2. Light yellow solid (99 mg, 53%). MS: m/z=411 (M+H+). Ames test negative.
출처 및 근거
- ORD 기록
- ord-4b063ffc8b44437bb7225a08aef761b4
- 출처 데이터셋
- uspto-grants-2016_01
- 특허 번호
- US09227970B2
연결된 노트
불러오는 중…